Nivolumab/SBRT Data Leave Role of Radiation Unclear in RCC

Wayne Kuznar
Published: Monday, Feb 17, 2020
Stereotactic body radiotherapy (SBRT) combined with nivolumab (Opdivo) was associated with “high” disease control and overall survival (OS) rates in a phase II study of pretreated patients with metastatic renal cell carcinoma (RCC); however, the combination did not meet the primary endpoint of overall response rate (ORR).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication